Loading
Disease Models, Animal / Streptococcal Infections · Journal article
Virulence · June 21, 2026
Encouraging direction, but not yet definitive.
This preclinical study demonstrates that blocking IL-17A activity or depleting neutrophils reduces mortality in mice infected with an ultra-virulent S. suis serotype 5 strain, implicating the IL-17A/neutrophil axis in pathogenesis. The findings identify a potential therapeutic target but require clinical translation to establish relevance to human STSLS management.
Preclinical experimental study (mouse infection model). Laboratory mice; infection model based on clinical isolate from human patient with STSLS and severe pneumonia. Intervention: IL-17A blockade and neutrophil depletion (antibody-mediated, dose-response examined). Compared with: Untreated infected control mice (implied).
IL-17A blockade effectively reduced mouse mortality at infection stages 1 and 2 Neutrophil depletion rescued mice from lethal infection and significantly reduced bacterial burden and IL-17A, IL-6, and TNF-α levels in peripheral blood Dose-dependent relationship observed between neutrophil-depleting antibody and protection from lethal infection
No quantitative effect sizes (e.g., hazard ratios, absolute mortality reduction) provided for mortality outcomes IL-17A blockade effectively reduced mouse mortality at infection stages 1 and 2
If confirmed in human studies, IL-17A inhibition or neutrophil-targeted therapy may offer a novel approach to reducing mortality in STSLS caused by ultra-virulent S. suis. Current evidence is mechanistic and preclinical; clinical utility remains unproven.
Mechanistic study in a mouse model of emerging pathogen infection identifies IL-17A/neutrophil axis as a therapeutic target, with functional evidence from blocking and depletion experiments showing reduced mortality, but limited by single-strain preclinical design without human efficacy data.
As stated by the source record.
Quoted from the source exactly as published.
If confirmed in human studies, IL-17A inhibition or neutrophil-targeted therapy may offer a novel approach to reducing mortality in STSLS caused by ultra-virulent S. suis. Current evidence is mechanistic and preclinical; clinical utility remains unproven.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Streptococcus suis (S. suis) is an important emerging zoonotic pathogen. In recent years, ultra-virulent serotype 5 clinical strains have emerged in China, characterized by causing high mortality in mice at early infection, even at low inoculation doses. In this study, we investigated the characteristics of lethal infection induced by the ultra-virulent S. suis serotype 5 strain SC2022MYS167 isolated from a patient with Streptococcal toxic shock-like syndrome (STSLS) and severe pneumonia. The lethal infection was associated with excessive bacterial loads and pro-inflammatory cytokines in peripheral blood and organs. Blocking IL-17A activity effectively reduced mouse mortality at infection stages 1 and 2. The lung tissues exhibited significantly higher levels of pro-inflammatory cytokines compared to liver and spleen tissues, with elevated IL-17A levels observed exclusively in the lung tissues of moribund mice at infection stage 1. CD11b+ Ly6G+ neutrophils recruited from peripheral blood significantly colocalized with IL-17A within lung tissues. Post-infection depletion of neutrophils rescued mice from lethal infection by significantly reducing the bacterial burden and levels of IL-17A, IL-6, and TNF-α in peripheral blood. A dose-dependent relationship was observed between neutrophil-depleting antibody and protection from lethal infection. These findings indicate the critical role of the IL-17A - neutrophil axis in STSLS development, pulmonary inflammation, pathological lesions, and subsequent acute host death induced by ultra-virulent serotype 5 strains, thereby providing a promising therapeutic target for reducing patient mortality.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.